Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03724851 | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | completed | Phase 1 / Phase 2 | 120 | MedPacto, Inc.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT03195699 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers |
| completed |
| Phase 1 |
| 64 |
| Tvardi Therapeutics, IncorporatedINDUSTRY |
| 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT00545545 | Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 32 | HiberCell, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 95 | MacroGenicsINDUSTRY | 5 | Mar 17, 2025 | clinicaltrials |
| NCT04247165 | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.(LAPTOP) | completed | Phase 1 / Phase 2 | 55 | Herlev HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05023928 | Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer | completed | Phase 1 | 25 | Sichuan UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT03829410 | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | completed | Phase 1 / Phase 2 | 68 | Cardiff OncologyINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02345408 | Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma | completed | Phase 1 | 54 | AmgenINDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT05303090 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 56 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT01148849 | Safety Study of MGAH22 in HER2-positive Carcinomas | completed | Phase 1 | 66 | MacroGenicsINDUSTRY | 2 | Feb 26, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05087992 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 5 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05943041 | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | completed | Phase 1 | 9 | GILongevityINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04805307 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | completed | Phase 1 | 176 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01649271 | Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02188264 | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05278728 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 31 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03916510 | Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer(CEDAR) | completed | Phase 1 | 12 | University of OxfordOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04883775 | Study of a New Technique for Imaging Pancreatic Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04662112 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma(NASOX) | completed | Phase 1 / Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03699319 | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 49 | David Bajor, MDOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03127007 | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer(R-IMMUNE) | completed | Phase 1 / Phase 2 | 45 | Grand Hôpital de CharleroiOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT03535727 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02643498 | A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03518554 | A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01950403 | Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03698825 | TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer | completed | Phase 1 / Phase 2 | 62 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | completed | Phase 1 | 10 | Karie D. Runcie, MDOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01010945 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | completed | Phase 1 | 19 | OSI PharmaceuticalsINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 25, 2025source: clinicaltrials